Foretinib
 | |
| Names | |
|---|---|
| IUPAC name
N1’-[3-fluoro-4-[[6-methoxy-7-(3-morpholinopropoxy)-4-quinolyl]oxy]phenyl]-N1-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide | |
| Other names
XL880; EXEL-2880; GSK1363089; GSK089 | |
| Identifiers | |
849217-64-7  | |
| ChEMBL | ChEMBL1908393 |
| ChemSpider | 24608641 |
| |
| Jmol-3D images | Image |
| |
| UNII | 81FH7VK1C4 |
| Properties | |
| Molecular formula |
C34H34F2N4O6 |
| Molar mass | 632.65 g·mol−1 |
| Except where noted otherwise, data is given for materials in their standard state (at 25 °C (77 °F), 100 kPa) | |
| Infobox references | |
Foretinib is an experimental drug candidate for the treatment of cancer.[1] It was discovered by Exelixis and is under development by GlaxoSmithKline.[2] It is currently in Phase II clinical trials.[3] As of December 2012 no phase III trials are registered.[3]
Foretinib is an inhibitor of the kinase enzymes c-Met and vascular endothelial growth factor receptor 2 (VEGFR-2).[4]
See also
- c-Met inhibitors
- Cabozantinib, a similar molecule and kinase inhibitor with FDA approval
- VEGFR inhibitor
- tyrosine-kinase inhibitor
References
- ↑ Hedgethorne, K., Huang, P.H. (2010). "Foretinib. c-Met and VEGFR-2 inhibitor, Oncolytic". Drugs Fut 35 (11): 893–901. doi:10.1358/dof.2010.35.11.1529012 (inactive 2015-01-13).
- ↑ "XL880 (GSK1363089)". Exelixis, Inc.
- ↑ 3.0 3.1 "Foretinib". clinicaltrials.gov.
- ↑ Qian, F; Engst, S; Yamaguchi, K; Yu, P; Won, KA; Mock, L; Lou, T; Tan, J et al. (2009). "Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases". Cancer Research 69 (20): 8009–16. doi:10.1158/0008-5472.CAN-08-4889. PMID 19808973.